您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > ERK-IN-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ERK-IN-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ERK-IN-1图片
规格:98%
分子量:578.42
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
ERK-IN-1(compoundB)是RAF和ERK1/2的抑制剂,通过激活MAPK通路中的突变来治疗增生性疾病。这种活性与KRAS-突变型非小细胞肺癌、BRAF-突变型非小细胞肺癌、KRAS-突变型胰腺癌、KRAS-突变型结肠癌以及KRAS-突变型卵巢癌尤为相关。
货号:ajcx12908
CAS:1715025-32-3
分子式:C26H27BrF3N5O2
分子量:578.42
溶解度:Soluble in DMSO
纯度:98%
存储:Store at -20°C
库存:现货

Background:

ERK-IN-1 (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1].


ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1].|| Animal Model:|Calu-6 NSCLC xenograft tumor models in mice[1].|Dosage:|50, 75 mg/kg.|Administration:|Orally either daily (qd) or every other day (q2d) for 27 days.|Result:|Significantly reduced the tumor volume.

[1]. WO2018051306A1.